PODD vs TXG: fair value comparison
Insulet Corporation and 10x Genomics, Inc. · Updated 2026-10-19
TXG has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PODD currently ranks higher by quality score.
| PODD | TXG | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $135.28 | $69.86 |
| 12-month range | $130.47–$346.36 | $12.44–$97.74 |
| Rank by discount to fair value | #96 of 108 Healthcare | — |
| Rank by quality score | #44 of 301 Healthcare | #45 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: PODD fair value analysis · TXG fair value analysis